ABSTRACT
Objectives Couple-based studies have considered human papillomavirus (HPV) transmission between current heterosexual partners (male↔female). Using data from young women and their sequential male partners in the HPV Infection and Transmission among Couples through Heterosexual activity (HITCH) study, we analysed HPV transmission from upstream sexual partnerships (male 1↔female) to downstream sex partners (→male 2).
Methods Among 502 females enrolled in the HITCH study (2005-2011, Montréal, Canada), 42 brought one male sex partner at baseline (male 1) and another during follow-up (male 2). Female genital samples, collected at 6 visits over 24 months, and male genital samples, collected at 2 visits over 4 months, were tested for 36 HPV types (n=1512 detectable infections). We calculated observed/expected ratios with 95% confidence intervals (CIs) for type-specific HPV concordance between males 1 and 2. Using mixed-effects regression, we estimated odds ratios (ORs) with 95% CIs for male 2 testing positive for the same HPV type as male 1.
Results Detection of the same HPV type in males 1 and 2 occurred 2.6 times (CI:1.9-3.5) more often than chance. The OR for male 2 positivity was 4.2 (CI:2.5-7.0). Adjusting for the number of times the linking female tested positive for the same HPV type attenuated the relationship between male 1 and 2 positivity, suggesting mediation.
Conclusions High type-specific HPV concordance between males 1 and 2 confirms HPV’s transmissibility in chains of sequential young adult sexual partnerships. HPV positivity in an upstream partnership predicted positivity in a downstream male when the linking female partner was persistently positive.
Competing Interest Statement
A.W.A. received a graduate stipend from the Gerald Bronfman Department of Oncology, McGill University and a presenter's award from the Experimental Medicine Graduate Students' Society, McGill University. M.Z. and E.L.F. hold a patent related to the discovery “DNA methylation markers for early detection of cervical cancer,” registered at the Office of Innovation and Partnerships, McGill University, Montréal, Québec, Canada (October 2018). F.C. reports grants from Réseau FRQS-SIDA during the conduct of the study, and grants to his institution for HPV-related work from Merck Sharp and Dome, Roche Diagnostics and Becton Dickinson outside of the submitted work. All other authors report no potential conflicts.
Clinical Protocols
Funding Statement
The HITCH cohort study was supported by the Canadian Institutes of Health Research [grant MOP-68893 and team grant CRN-83320 to E.L.F.] and the US National Institutes of Health [grant RO1AI073889 to E.L.F.]. A.N.B. is a Canada Research Chair in Sexually Transmitted Infection Prevention and a recipient of a University of Toronto Department of Family and Community Medicine Non-Clinician Scientist award. Supplementary and unconditional funding support to the HITCH study was provided by Merck-Frosst Canada and Merck & Co.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
HITCH complies with all national/international regulations regarding research with human data and materials, including the Declaration of Helsinki. The study was conducted per the principles and articles stipulated by the Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans. Ethical approval was obtained from the institutional review boards at McGill University, Concordia University, and the Centre Hospitalier de l'Université de Montréal. Ethics renewal approval is requested annually from McGill University (study number A09-M77-04A). All subjects provided written informed consent for study participation.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
HITCH participant consent forms specified that data would be published in aggregate form and that individual-level data would only be available to study investigators. To access individual-level data, please contact Eduardo Franco at eduardo.franco{at}mcgill.ca. Analytical codes and a data dictionary are available on the McGill University Dataverse.
